Role of Bispecifics and Future Promising Treatments in DLBCL
Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.
The Future of DLBCL Treatment
A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.
Management and Work-up of Patients for Salvage Therapy
The panelists share their approach to the treatment and work-up of patients who require salvage therapy.
Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy
Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.
A Closer Look at CAR T-Cell Therapy Clinical Trial Design
Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.
Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL
Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.
Therapeutic Sequencing and Bridging in DLBCL
Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.
Treating Patients Who Relapse or Progress on CAR T-Cell Therapy
Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.
A Closer Look at the Potential Impact of Bispecific Antibodies on the DLBCL Treatment Landscape
Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.
Comparing Real-World Evidence With Data From Clinical Trials
The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.
Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL
Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.
Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL
Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.
Improving Outcomes in Patients With DLBCL
Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.
A Focus on Frontline Treatment in Patients With DLBCL
Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.
Concluding Thoughts on the DLBCL Treatment Landscape
DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.
Use of CAR T-Cell Therapies in Earlier Lines of DLBCL
Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.
Monoclonal Antibodies for Treatment of R/R DLBCL
Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.
Real-World Data With CAR-T Therapies in R/R DLBCL
Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.
Safety With CAR-T Therapies in R/R DLBCL
Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.
CAR-T Therapies in R/R DLBCL
Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.